Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.

We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.’s share was trading at $47.84 as ...

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Harrow, Inc. recently reported third-quarter 2025 results, highlighting a revenue increase to US$71.64 million and a move from a net loss to a net profit compared to the same period last year. The ...

Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Constance Grady is a senior correspondent on the Culture team for Vox, where since 2016 she has covered books, publishing, gender, celebrity analysis, and theater. I couldn’t tell that there was ...

Please provide your email address to receive an email when new articles are posted on . Harrow will inherit MELT-300, a sublingually delivered sedation product. The company plans to submit a new drug ...